Key result
Intraosseous administration of 0.1 mg/kg adenosine successfully terminated a supraventricular tachycardia attack in a 28-day-old male newborn.
Why the study?
Supraventricular tachycardia is rare in the neonatal period, occurring with an incidence of 0.6/1000 in newborns.
Does intraosseous adenosine administration terminate supraventricular tachycardia in a newborn?
Case Report (n=1)
No
Does intraosseous adenosine administration terminate supraventricular tachycardia in a newborn?
Intraosseous adenosine administration is a viable and successful method for terminating supraventricular tachycardia in newborns.
May offer alternative adenosine route in neonatal SVT; hypothesis-generating case report requiring prospective validation.
BACKGROUND: Supraventricular tachycardia (SVT) is the most common type of tachycardia in childhood. The incidence is 1-4/1000 in childhood and 0.6/1000 in newborns. CASE: Here we report a 28-day-old male newborn who was diagnosed SVT, admitted to the Pediatric Emergency Department after restlessness that had started three hours before admission and measurement of the heart rate was above 250 beats/min. CONCLUSIONS: This case is presented in order to emphasize that SVT is rare in the neonatal period and SVT is successfully terminated with the administration of intraosseous adenosine.
No takes yet. Share an insight, caveat, or question.
Fidancı et al. (2020) conducted a case report in Supraventricular tachycardia (n=1). Intraosseous adenosine was evaluated on Termination of supraventricular tachycardia. Intraosseous administration of 0.1 mg/kg adenosine successfully terminated a supraventricular tachycardia attack in a 28-day-old male newborn.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: